Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Agenus
AGEN
Agenus
Regulatory Pressure And Cash Burn Will Challenge Immuno-Oncology Prospects Yet Clinical Progress Will Persist
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
15 Aug 25
Updated
15 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$6.00
26.8% undervalued
intrinsic discount
15 Aug
US$4.39
1Y
-25.2%
7D
-3.1%
Loading
1Y
-25.2%
7D
-3.1%
Author's Valuation
US$6.0
26.8% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$6.0
26.8% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-263m
320m
2014
2017
2020
2023
2025
2026
2028
Revenue US$95.1m
Earnings US$15.2m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
8.05%
Biotech revenue growth rate
11.91%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.66%
Calculation
US$15.17m
Earnings '28
x
34.52x
PE Ratio '28
=
US$523.73m
Market Cap '28
US$523.73m
Market Cap '28
/
70.01m
No. shares '28
=
US$7.48
Share Price '28
US$7.48
Share Price '28
Discounted to 2025 @ 7.64% p.a.
=
US$6.00
Fair Value '25
